President Trump announced a sudden 100% tariff on branded pharmaceutical imports starting October 1, 2025, unless companies build manufacturing plants in the US. Generic drugs and companies with active US construction plans are exempt. Experts anticipate confusion over definitions and potential cost increases for US consumers, despite some companies already pledging US investment. Top exporting countries like Ireland, Germany, and India may be significantly impacted.

Prepared by Christopher Adams and reviewed by editorial team.